Friday, October 11, 2024 11:14:17 AM
You are wrong.
First, comparing the bespoke, groundbreaking DCVax platform to a standardized, one-size-fits-all drug is flawed. They are worlds apart and cannot be assessed by the same criteria. It's like trying to wear a glove that just doesn’t fit.
Second, it seems you've overlooked the potential of DCVax to become the universal treatment for all tumor-based cancers.
Third, considering DCVax’s highly personalized and effective nature, wouldn't a franchise model be more advantageous? It could foster much more competition, benefiting patients, the industry, shareholders, and NWBO itself, rather than letting a single pharmaceutical giant monopolize it.
First, comparing the bespoke, groundbreaking DCVax platform to a standardized, one-size-fits-all drug is flawed. They are worlds apart and cannot be assessed by the same criteria. It's like trying to wear a glove that just doesn’t fit.
Second, it seems you've overlooked the potential of DCVax to become the universal treatment for all tumor-based cancers.
Third, considering DCVax’s highly personalized and effective nature, wouldn't a franchise model be more advantageous? It could foster much more competition, benefiting patients, the industry, shareholders, and NWBO itself, rather than letting a single pharmaceutical giant monopolize it.
“When bad men combine, the good must associate; else they will fall one by one, an unpitied sacrifice in a contemptible struggle.”
~Edmund Burke
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
